AMW is an innovative specialty pharmaceutical company, which initially starting 2008 life as a CDMO, now develops and markets own proprietary bio-degradable sustained-release drug delivery systems and out-licenses these to international pharmaceutical companies. Products developed by AMW enable the administration of drugs via implants (subcutaneous). We have apart from a Leuprorelide implant the only international available generic of Goserelin implants.
Location: Germany, Bavaria, Warngau
Employees: 51-200
Total raised: $36.52M
Founded date: 2008
Investors 5
| Date | Name | Website |
| 15.03.2022 | BayBG | baybg.de |
| - | Unternehme... | uvcpartner... |
| - | BayBG Vent... | baybg-vc.d... |
| - | SHS Gesell... | shs-capita... |
| 04.06.2023 | IPF Partne... | ipfpartner... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.01.2018 | - | $30.17M | - |
| 30.11.2016 | - | $6.36M | - |
Mentions in press and media 2
| Date | Title | Description |
| 04.01.2018 | AMW Receives €25M from EIB | AMW GmbH, a German pharmaceutical company specialized in the development and manufacturing of innovative drug delivery systems, received €25m. The European Investment Bank (EIB) will provide the financing. The funds will support the company... |
| 30.11.2016 | AMW Raises €6m in Funding | AMW GmbH, a Warngau, a near Munich, Germany-based medical technology company, raised €6m in funding. Backers included the Bavarian growth fund Wachstumsfonds Bayern, which is managed by Bayern Kapital, and SHS Gesellschaft für Beteiligungsm... |